Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

Opinion|Videos|January 27, 2025

A Case of PPD in a Mother With a History of Major Depressive Disorder

Author(s)Carmen Kosicek, MSN, PMHNP-BC, Deb York, MSN, PMHNP-BC, APRN, CCRA

Panelists discuss the case of Sarah, a 29-year-old woman with a history of major depressive disorder who is struggling with postpartum adjustment and increasing isolation, highlighting the challenges of transitioning into motherhood, family dynamics, and the potential genetic and environmental factors influencing her mental health.

Episodes in this series

EP. 1 Overview of PPD and Current Management Practices

EP. 1 Overview of PPD and Current Management Practices

EP. 2 New FDA-Approved Treatments for PPD

EP. 2 New FDA-Approved Treatments for PPD

EP. 3 The Case of a 34-Year-Old Woman With PPD After the Birth of her Third Child

EP. 3 The Case of a 34-Year-Old Woman With PPD After the Birth of her Third Child

EP. 4 Diagnostic Tools for PPD

EP. 4 Diagnostic Tools for PPD

EP. 5 Treatment Choices For PPD and Peripartum Depression

EP. 5 Treatment Choices For PPD and Peripartum Depression

EP. 6 Monitoring Treatment Response and Challenges in Managing PPD Patients in Ob/Gyn Practices

EP. 6 Monitoring Treatment Response and Challenges in Managing PPD Patients in Ob/Gyn Practices

EP. 7 A Case of PPD in a Mother With a History of Major Depressive Disorder

EP. 7 A Case of PPD in a Mother With a History of Major Depressive Disorder

EP. 8 Assessing Symptoms, Treatment Decision-Making, and Monitoring

EP. 8 Assessing Symptoms, Treatment Decision-Making, and Monitoring

EP. 9 Supporting Mothers With Postpartum Depression and Promoting Culturally Sensitive Care

EP. 9 Supporting Mothers With Postpartum Depression and Promoting Culturally Sensitive Care

postpartum depression

EP. 10 Experts Share Top 7 Recommendations for Treating Postpartum Depression

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Related Content

5 experts are featured in this series

Differentiating Agitation from Depression, Anxiety, and Psychosis

ByMarwan Sabbagh, MD, FAAN, FANA,Amita R. Patel, MD, CMD, MHA, CPE,Erin Crown, MHS, PA-C, Psych-CAQ,David Liporace, DO,Laura Melaro, DNP, APRN, FNP-BC, PMHNP-BC

September 4th 2026

5 experts are featured in this series

Agitation Associated with Dementia Due to Alzheimer’s Disease: How Common Is It, and How Does It Present?

ByMarwan Sabbagh, MD, FAAN, FANA,Amita R. Patel, MD, CMD, MHA, CPE,Erin Crown, MHS, PA-C, Psych-CAQ,David Liporace, DO,Laura Melaro, DNP, APRN, FNP-BC, PMHNP-BC

September 4th 2026

Screening for MDD: Distinguishing Depression From Grief and Medical Mimics

ByGus Alva, MD ,Anita H. Clayton, MD,Charles Debattista, MD,Lara Shirikjian, MD ,Hara Oyedeji, DNP, PMHNP-BC

July 28th 2026

Recognizing MDD in Practice: Presentation, Risk Factors, and Delayed Diagnosis

ByGus Alva, MD ,Anita H. Clayton, MD,Charles Debattista, MD,Lara Shirikjian, MD ,Hara Oyedeji, DNP, PMHNP-BC

July 28th 2026

Experts featured in this series.

Multidisciplinary Approaches to Long-Term Narcolepsy Care

ByKarl Doghramji, MD, FAASM, DFAPA,Michael Strunc, MD,Ellen Wermter, FNP-BC, DBSM, FAASM,W. Christopher Winter, MD

April 22nd 2026

Latest CME

Jersey City Psychiatry

In-Person Event

Jersey City Psychiatry

October 2-3, 2026

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Cases and Conversations™: Optimizing Administration of Treatment for Patients with Schizophrenia

Cases and Conversations™: Optimizing Administration of Treatment for Patients with Schizophrenia

Gus Alva, MD, DFAPA; Erin Crown, MHS, PA-C

Trending on Psychiatric Times

Repurposing Dopamine Agonist Pramipexole for Disabling Anhedonia

When Treatment-Resistant Depression Means Mismatched: Rethinking Difficult-to-Treat Depression

Brain Trust: Anita H. Clayton, MD, on Diagnosing and Treating Sexual Dysfunction

The Year So Far in GLP-1s: What Psychiatric Clinicians Need to Know

GLP-1 Receptor Agonists Linked to Lower Mortality, Cardiovascular Events in Serious Mental Illness